NCT03505996View on ClinicalTrials.gov

A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

May 22, 2018

Primary Completion Date

February 19, 2020

Study Completion Date

November 1, 2021

Conditions
Hodgkin Lymphoma
Interventions
BIOLOGICAL

CS1001

Monoclonal antibody

Trial Locations (1)

Unknown

Beijing Cancer Hospital, Beijing

Sponsors
All Listed Sponsors
lead

CStone Pharmaceuticals

INDUSTRY